[DOI] [PMC free article] [PubMed] [Google Scholar] 64.Rouse R, Zhang L, Shea K, Zhou H, Xu L, Stewart S, Rosenzweig B, Zhang J
Subsequent studies also examining data from the FDA Adverse Event Reporting System (FDA AERS) reported an increase in reporting rates of PDAC cases in GLP-1RA users over a broader study period 33,34
While some preclinical research has explored potential immunomodulatory effects of GLP-1 receptor agonists, there is currently insufficient clinical evidence to establish this as a mechanism for systemic symptoms in patients taking tirzepatide
Retatrutide is a triple agonist, meaning it activates three distinct hormone receptors GLP-1, GIP, and glucagon
Schwarz EI, Stradling JR, Kohler M
Prescription weight loss medications offer significant benefits for long-term weight management